The Worldwide Market for In Vitro Diagnostic Tests: 12th Edition
What is the Size of the 2019 IVD Market?
How fast will the market grow?
What companies stand to gain?
Kalorama has answered these questions for readers for two decades. Now in its 12th edition, this Kalorama Information report, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, is the most essential report on the IVD industry.
The market for IVD currently stands at $69.2 billion dollars. It is poised for growth over the next five years, improved growth from the last edition of Kalorama’s report. There are hundreds of companies competing in the market in some form, and scores of large multi-test players.
Kalorama’s 2,000-page report provides in vitro diagnostics market size estimates and projections for the entirety of the in vitro diagnostics testing market. It is a global report, a comprehensive report and a reliable report that has been industry standard for two decades.
- 2000-Page Report Based on Vendor Reporting, Interviews, Vendor Activities
- Authored by Veteran IVD Analysts with Industry Knowledge
- 12 Detailed Market Chapters with 2019 Market Estimate
- Relevant Segmentation for Test Business Planners, Investors, New Entrants and Other Market Watchers
- Where is IVD Heading? – Market Segment Projections to 2024
- What’s Behind the Growth and Declines? – Market Numbers and Analysis
- Regional Breakouts Including Country IVD Markets
- Sections on China, Europe, Japan and The United States IVD Markets
- Macro Analysis of Major Trends
- Superior Company Profiles of Top Tier Companies and Hundreds of Smaller Concerns
- Used by Major IVD Firms for Business Planning
- Coverage of Trends and Market Estimates for Essential IVD Segments: Clinical Chemistry, Point-of-Care, Molecular, Infectious Disease, Histology and More.
In vitro diagnostic testing costs little to the healthcare system and contributes much to clinical practice. For some time this has been stated as educated conjecture; a recent study of U.S and German physicians offers proof. The study found that 66% of clinical decisions made were based on a diagnostic test, while the costs of those tests were just 2.3% of healthcare expenditure (Rohr U., Binder C, PLoS One. 2016). When the cost-effectiveness of in vitro diagnostic testing is then considered along with beneficial effects on treatment outcomes, therapy choices, and hospital management, there should be little surprise about the amount of interest in IVDs and the amount of activity in the market for them.
The Worldwide Market for In Vitro Diagnostic (IVD) Tests estimates the current in vitro diagnostics market size and forecasted market size to 2024 for defined segments of the IVD market and various sub-segments, including:
- Molecular Assays: Infectious Disease [HIV, Hepatitis, Respiratory, Others] Blood Screening, Inherited Diseases, Oncology, PGx, Tissue Typing, Prenatal
- Clinical Chemistry and “Core Lab” Markets: General Chemistries, Blood Gases, Urinalysis, Immunos run on Workstations
- Point-of-Care Testing (POC): Professional and Self-Testing, Fertility, Colon Cancer, HbA1c POC, Influenza, HIV, STD, Hepatitis, Malaria, c.difficile, E.Coli, H.pylori, Home Test/OT
- Glucose Testing: Meters, Professional Testing, Continuous Glucose
- Substance Abuse Testing (Employment Screening, Criminal Justice, Critical Care – Traditional POC)
- Microbiology and Virology by Test Type (Immunoassays, ID/AST, Infectious Diseases – DNA; ID/AST: Panels and Reagents, automated; Panels and Reagents, manual; Blood Culture; Chromogenic Media; Rapid Micro; Supplies)
- Blood Banking (Typing, Immunoassay Screen, NAT Blood Testing)
- Histology and Cytology: Pap Tests, in situ hybridization, immunohistochemistry, traditional non-Pap stains, HPV
- Immunoassay Testing: Infectious Disease, Cardiac Markers, Tumor Markers, Autoimmune, Diabetes/HbA1c, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic Drugs, Drugs of Abuse, Vitamin D, Total; w/o HbA1c
- Hematology
- Cardiac Markers, Tumor Markers, Diabetes/hbA1c, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic Drugs
- Coagulation Tests
- Direct-to-Consumer Testing
For each of the listed in vitro diagnostics market segments, 2019 in vitro diagnostics market size, 2024 projection and compound annual growth rate is provided, as well as significant in vitro diagnostic companies in the market and IVD manufacturers’ product innovations. The market data is put into a context with real-world industry and medical practice trends. The Worldwide Market for In Vitro Diagnostic Tests has been called “The Bible of the IVD Industry” by customers, which include top IVD firms. Using Kalorama Information’s The Worldwide Market for In vitro Diagnostic (IVD) Tests, 12th Edition, ensures that your firm will have the perspective and data of others in the in vitro diagnostics industry, as well as of those who track and invest in the IVD industry.
The IVD Market Opportunity by Country
The in vitro diagnostics market is a global one, and The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 12th Edition reflects the international scope of the in vitro diagnostics market size. In the healthcare market, IVD companies sell globally and think globally. Trends in one part of the world affect IVD manufacturers’ product decisions and company financial performance in others. Thus, this is a global report, and the following regional and country overall IVD markets are included.
IVD Market Opportunity by Country is provided for the following countries: China, Philippines, Brazil, Israel, Malaysia, India, Mexico, Indonesia, Chile, Poland, Saudi Arabia, South Korea, Romania, Colombia, United Arab Emirates, Argentina, Hungary, Vietnam, Iraq, Peru, Japan, France, Turkey, Egypt, Singapore, Luxembourg, Croatia, Jordan, U.S., Germany, United Kingdom, Canada, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Denmark, Ireland, Finland, Iran, Thailand, Venezuela, Italy, Australia, Portugal, Greece, Czech Republic, South Africa, Norway, Bulgaria, Slovakia, Slovenia.
The Worldwide Market for In Vitro Diagnostic Tests is a testament to the Kalorama methodology. It is the result of months of painstaking work by an experienced IVD industry analyst, who has tracked hundreds of in vitro diagnostic companies for developments, trends and financial results. This research is compiled along with the opinion, observations and insights of industry experts to produce an unparalleled vision of the in vitro diagnostics industry as it is in 2019.
Who’s In The Market? Who’s Winning?
The report concentrates over a thousand pages on detailed and tiered profiles of companies in the in vitro diagnostics market. The experience that Kalorama Information has in the in vitro diagnostic market is evident in its tiering and segmentation of companies.
- Abbott Diagnostics
- Arkray
- Becton, Dickinson and Company (BD)
- Beckman Coulter, Inc. / Danaher
- bioMérieux Inc.
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- DiaSorin S.p.A
- Grifols S.A.
- Hologic, Inc.
- Instrumentation Laboratory (IL) / Werfen
- Ortho Clinical Diagnostics (Ortho)
- QIAGEN N.V.
- Radiometer A/S / Danaher
- Roche Diagnostics
- Siemens Healthineers (Siemens)
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Werfen
- Agilent Technologies
- BGI Genomics (formerly Beijing Genome Institute)
- Bruker Corporation
- Cepheid
- Eiken Chemical Co., Ltd
- Fujirebio Diagnostics, Inc.
- Illumina
- LabCorp, Laboratory Corporation of America
- Leica Biosystems
- Luminex Corporation
- A. Menarini Diagnostics
- Meridian Bioscience, Inc.
- Mindray – Shenzhen Mindray Bio-medical Electronics Co., Ltd.
- Nova Biomedical Corporation (Nova)
- PerkinElmer, Inc. (PE)
- Philips (Royal Philips)
- Quest Diagnostics
- Quidel Corporation
- Randox Laboratories Ltd.
- Ventana Medical Systems Inc. / Roche Tissue Diagnostics
- Diagnostica Stago, S.A.S.
- AB SCIEX Pte Ltd
- EKF Diagnostics Holdings Plc
- ELITech Group S.A.S.
- ERBA Diagnostics, Inc.
- MedTest DX
- Microsaic Systems plc
- Nova Biomedical
- Scienion AG
- Sekisui Diagnostics LLC
- Shimadzu Scientific Instruments
- Snibe Co. Ltd., (Shenzhen New Industries Biomedical Engineering Co. Ltd.)
- Tecan Group
- Tosoh Bioscience
- Trinity Biotech Plc
- Biocartis
- Biocept, Inc.
- Biodesix
- Cynvenio Biosystems (LungLife AI)
- Epigenomics AG
- Foundation Medicine, Inc.
- Genomic Health (Exact Sciences)
- Guardant Health, Inc.
- Menarini-Silicon Biosystems
- Myriad Genetics, Inc.
- Natera
- NeoGenomics
- Dexcom Inc.
- Gentag Inc.
- LifeScan Inc.
- Medtronic plc
- Nemaura Medical Inc.
- CellaVision AB
- Horiba Medical
- Medica Corporation
- Onca Xt Ltd
- West Medica
- Advanced Cell Diagnostics (ACD)
- Amoy Diagnostics Co. Ltd.
- Applied Spectral Imaging Inc. (ASI)
- BioGenex Laboratories, Inc.
- BioView Ltd.
- Circulomics Inc.
- Dako A/S
- Definiens
- HTG Molecular Diagnostics
- Kapa Biosystems Inc.
- Leica Biosystems
- MilliporeSigma (formerly EMD Millipore)
- Biohit Oyj (Biohit Healthcare)
- Biomerica Inc.
- Bio-Techne Corporation
- Corgenix Medical Corporation
- Critical Diagnostics
- Eurobio Scientific
- EUROIMMUN AG
- HOB Biotech
- Immunodiagnostic Systems (IDS)
- INOVA Diagnostics, Inc.
- Cerner Corp.
- Dell Technologies Inc.
- Desktop Genetics Ltd.
- Accelerate Diagnostics, Inc.
- Advanced Biological Laboratories, S.A. (ABL)
- altona Diagnostics
- ArcDia International Oy Ltd.
- BioFire Diagnostics, LLC. (acquired by bioMérieux)
- Bruker BioSciences Corporation
- COPAN ITALIA S.p.A. and COPAN Diagnostics, Inc.
- Curetis
- Fast Track Diagnostics (acquired by Siemens Healthineers)
- Focus Diagnostics, Inc.
- Genetic Analysis AS
- Greiner Bio-One International GmbH
- Hain Lifescience GmbH
- Mast Group
- Mobidiag Ltd.
- Nanosphere, Inc. (Luminex)
- OpGen, Inc.
- PositiveID Corporation
- Q-linea AB
- Seegene, Inc.
- Asuragen Inc.
- AutoGenomics Inc.
- Enzo Biochem Inc.
- Exosome Diagnostics, Inc.
- Fluidigm Corporation
- GenMark Diagnostics, Inc
- Genome Diagnostics BV (GenDx)
- NanoString Technologies, Inc.
- Oxford Nanopore Technologies Ltd
- Pacific Biosciences of California, Inc. (PacBio)
- QuanDx Inc
- RainDance Technologies, Inc.
- Rubicon Genomics, Inc.
- Takara Bio Inc.
- Trovagene, Inc.
- Vela Diagnostics
- WaferGen Bio-systems, Inc.
- Abaxis, Inc.
- Abingdon Health Ltd.
- Atlas Genetics Ltd. (Binx Health)
- Biomeme, Inc.
- Chembio Diagnostic Systems, Inc.
- DNA Electronics Ltd (DNAe)
- Entopsis
- FABPulous B.V.
- Fio Corporation
- Genedrive plc (formerly Epistem Holdings)
- PTS Diagnostics
- QuantuMDx Group, Ltd.
- Rheonix, Inc.
- Samsung Healthcare
- Veredus Laboratories Pte Ltd
- and others …